Elucidation of the binding regions of PAI-1 neutralizing antibodies using chimeric variants of human and rat PAI-1

Thrombosis and Haemostasis

Volumn 85, Issue 5, 2001, Pages 866-874

  Bijnens, A P ^a   Ngo, T H ^a   Gils, A ^a   Dewaele, J ^a   Knockaert, I ^a   Stassen, J M ^a   Declerck, P J ^a  

^a UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

Antibody; Chimera; Epitope; PAI 1; Serpin

Indexed keywords

MONOCLONAL ANTIBODY; PLASMINOGEN ACTIVATOR INHIBITOR 1; TISSUE PLASMINOGEN ACTIVATOR;

AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; ARTICLE; BINDING AFFINITY; BINDING SITE; CARDIOVASCULAR DISEASE; CHIMERA; CONTROLLED STUDY; CROSS REACTION; DRUG DESIGN; ENZYME LINKED IMMUNOSORBENT ASSAY; EPITOPE MAPPING; HUMAN; INHIBITION KINETICS; MOLECULAR STABILITY; MUTAGENESIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN CONFORMATION; RAT; RISK FACTOR; SURFACE PLASMON RESONANCE; THROMBOEMBOLISM;

EID: 0035002340     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0037-1615761     Document Type: Article

References (49)

1. Demonstration of a fast-acting inhibitor of plasminogen activators in human plasma
2. Cloning and sequence of a cDNA coding for the human beta-migrating endothelial-cell-type plasminogen activator inhibitor
3. Endothelial plasminogen activator inhibitor (PAI): A new member of the Serpin gene family
4. Reactivated recombinant plasminogen activator inhibitor-1 (rPAI-1) effectively prevents thrombolysis in vivo
5. Lysis of platelet-rich thrombi: The role of PAI-1
6. Pathophysiology of fibrinolysis
7. A critical review of the evidence supporting a relationship between impaired fibrinolytic activity and venous thromboembolism
8. Predictive value of fibribolytic factors in coronary heart disease
9. Purification and characterization of a plasminogen activator inhibitor-1 binding protein from human plasma. Identification as a multimetric form of S protein (vitronectin)
10. Absence of host plasminogen activator inhibitor 1 prevents cancer invasion and vascularization
11. Plasminogen activator inhibitor-1 gene deficient mice. II. Effects on hemostasis, thrombosis and thrombolysis
12. Development of venous occlusions in mice transgenic for the plasminogen activator inhibitor-1 gene
13. Inhibition of plasminogen activator inhibitor-1 activity results in promotion of endogenous thrombolysis and inhibition of thrombus extension in models of experimental thrombosis
14. Thrombolysis and reocclusion in experimental jugular vein and coronary artery thrombosis. Effects of a plasminogen activator inhibitor type 1-neutralizing monoclonal antibody
15. Antithrombotic activity of a monoclonal antibody inducing the substrate form of plasminogen activator inhibitor type 1 in rat models of venous and arterial thrombosis
16. Peptide-mediated inactivation of recombinant and platelet plasminogen activator-1 in vitro
17. Inhibitory mechanism of serpins: Loop insertion forces acylation of plasminogen activator by plasminogen activator inhibitor-1
18. Interfering with the inhibitory mechanism of serpins: Crystal structure of a complex formed between cleaved plasminogen activator inhibitor type 1 and a reactive-centre loop peptide
19. Inhibition of plasminogen activator inhibitor 1 activity by two diketopiperazines, XR330 and XR334 produced by Streptomyces species
20. Evaluation of a low molecular weight modulator of human plasminogen activator inhibitor-1 activity
21. Novel low molecular weight inhibitor of PAI-1 (XR5118) promotes endogenous fibrinolysis and reduces postthrombolysis thrombus growth in rabbits
22. XR5118, a novel modulator of plasminogen activator inhibitor 1 (PAI-1), increases endogenous tpa activity in the rat
23. Identification of the binding site for a low-molecular-weight inhibitor of plasminogen activator inhibitor type 1 by site- directed mutagenesis
24. Sideroxylonal C, a new inhibitor of human plasminogen activator inhibitor type-1, from the flowers of Eucalyptus albens
25. Comparative analysis of PAI-1 inhibitors
26. Neutralization of plasminogen activator inhibitor-1 inhibitory properties: Identification of two different mechanisms
27. Structure-function relationship in serpins: Current concepts and controversies
28. Endothelial cells produce a latent inhibitor of plasminogen activators that can be activated by denaturants
29. Identification of a conformationally distinct form of plasminogen activator inhibitor-1, acting as a noninhibitory susbtrate for tissue-type plasminogen activator
30. A substrate-like form of plasminogen-activator-inhibitor type 1. Conversions between different forms by sodium dodecyl sulphate
31. Interconversions between active, inert and substrate forms of denature/refolded type-1 plasminogen activator inhibitor
32. Definition of epitopes within plasminogen activator inhibitor type-1 (PAI-1) using multiple peptide synthesis
33. Identification of functional interaction sites on proteins using bacteriophage displayed random epitope libraries
34. Identification of a functional epitope in plasminogen activator inhibitor-1, not localized in the reactive center loop
35. The interaction of plasminogen activator inhibitor 1 with plasminogen activators (tissue-type and urokinase-type) and fibrin: Localization of interaction sites and physiologic relevance
36. Importance of the hinge region between a-helix F and the main part of serpins, based upon identification of the epitope of plasminogen activator inhibitor type 1 neutralizing antibodies
37. Localization of a vitronectin binding region of plasminogen activator inhibitor-1
38. Substrate behavior of plasminogen activator inhibitor-1 is not associated with a lack of insertion of the reactive site loop
39. Expression, purification and characterization of recombinant rat plasminogen inhibitor-1
40. Evidence for the occurrence of a fast-acting inhibitor for tissue-type plasminogen activator in human plasma
41. Receptor and antibody epitopes in human growth hormone identified by homolog-scanning mutagenesis
42. Structure-function studies of the serpin plasminogen activator inhibitor type 1. Analysis of chimeric strained loop mutants
43. Rational design of complex formation between plasminogen activator inhibitor-1 and its target proteinases
44. Plasminogen activator inhibitor 1. Structure of the native serpin, comparison to its other conformers and implications for serpin inactivation
45. High-density mutagenesis by combined DnA shuffling and phage display to assign essential amino acid residues in protein-protein interactions: Applications to study structure-function of plasminogen activator inhibitor 1 (PAI-1)
46. Epitopes on plasminogen activator inhibitor type 1 important for binding to tissue plasminogen activator
47. Identification of functional synergism between monoclonal antibodies. Application to the enhancement of plasminogen activator inhibitor-1 neutralizing effects